Analyst Valuation and EPS Growth Sonoma Pharmaceuticals (NASDAQ:SNOA)

Earnings results for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals, Inc. is estimated to report earnings on 11/12/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.91.

Sonoma Pharmaceuticals last announced its earnings results on August 14th, 2020. The reported $0.02 EPS for the quarter. The business earned $7.25 million during the quarter. Sonoma Pharmaceuticals has generated $0.00 earnings per share over the last year. Sonoma Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 12th, 2020 based off prior year’s report dates.

Analyst Opinion on Sonoma Pharmaceuticals (NASDAQ:SNOA)

Dividend Strength: Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals does not currently pay a dividend. Sonoma Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: Sonoma Pharmaceuticals (NASDAQ:SNOA)

In the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock. Only 5.60% of the stock of Sonoma Pharmaceuticals is held by insiders. Only 7.01% of the stock of Sonoma Pharmaceuticals is held by institutions.

Earnings and Valuation of Sonoma Pharmaceuticals (NASDAQ:SNOA

The P/E ratio of Sonoma Pharmaceuticals is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Sonoma Pharmaceuticals is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Sonoma Pharmaceuticals has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here